UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 9, 2017
Axovant Sciences Ltd.
(Exact name of registrant as specified in its charter)
|
Bermuda |
|
001-37418 |
|
98-1333697 |
|
(State or other jurisdiction of |
|
(Commission File No.) |
|
(I.R.S. Employer Identification No.) |
|
Clarendon House - 2 Church Street |
|
Not Applicable |
|
(Address of principal executive office) |
|
(Zip Code) |
Registrant’s telephone number, including area code: +1 (441) 824-8100
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On January 9, 2017, Axovant Sciences Ltd. (“Axovant”) issued a press release providing its estimated cash balance as of December 31, 2016. This amount is preliminary, unaudited and subject to change upon completion of Axovant’s review of its financial statements as of and for the quarterly period ended December 31, 2016. Additional information and disclosures would be required for a more complete understanding of Axovant’s financial position and results of operations as of December 31, 2016. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.
In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release of Axovant Sciences Ltd., dated January 9, 2017, “Axovant Sciences Announces Pipeline Program Updates and Presentation at 35th Annual J.P. Morgan Conference” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Axovant Sciences Ltd. | |||
|
|
| |||
|
|
|
| ||
|
Date: |
January 9, 2017 |
|
By: |
/s/ Gregory Weinhoff |
|
|
|
Name: |
Gregory Weinhoff | |
|
|
Title: |
Principal Financial Officer | ||